Obesity and chronic disease prevention, specifically cardiovascular disease and type 2 diabetes Nutritional, Metabolic, Endocrine Obesity and chronic disease prevention, specifically cardiovascular disease and type 2 diabetes
Conditions
Interventions
Current interventions as of 10/09/2021:
This study involves two phases: an internal pilot and the full study. Participants are allocated to clusters which are randomised to receive either the six mont
Sponsors
Loughborough University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Long distance heavy goods vehicle (HGV) drivers 2. Aged 18 to 65 years 3. Male and female (with the exception of females who are pregnant) 4. Free of cardiovascular disease, haemophilia, or blood-borne viruses 5. Must not have any mobility issues which prevent them from going about their normal work duties
Exclusion criteria
Exclusion criteria: 1. Cardiovascular disease 2. Haemophilia 3. Any blood-borne viruses or mobility limitations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 10/09/2021: Physical activity (steps per day) is measured using the activPAL3 micro accelerometer (worn on the thigh 24 hours a day during the 7 day assessment period) at baseline and 6 months Previous primary outcome measure: Physical activity (steps per day) is measured using the activPAL3 micro accelerometer (worn on the thigh 24 hours a day during the 7 day assessment period) at baseline, 6 months and 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 10/09/2021: 1. Light and moderate-to-vigorous physical activity (MVPA) is measured using the GENEActiv accelerometer (worn on the wrist 24 hours a day for the 7 day assessment period at baseline, 6 months, and 8-11 months 2. Sitting time is measured using the activPAL3 micro at baseline, 6 months, and 8-11 months 3. Adiposity measured using the portable Tanita 418 bioelectrical impedance analyser at baseline and 6 months 4. Neck circumference is measured using anthropometry tape at baseline and 6 months 5. Blood pressure is measured using automated blood pressure analysers at baseline and 6 months 6. Blood markers (total cholesterol, HDL, LDL, glycated haemoglobin) are assessed using a finger-prick blood sample at baseline and 6 months 7. Dietary quality is measured using a short-form food frequency questionnaire at baseline, 6 months, and 8-11 months 8. Binge eating is measured using The Three-Factor Eating Questionnaire at baseline, 6 months, and 8-11 months 9. Sleep duration is measured using the GENEActiv for 7 days at baseline and 6 months 10. Sleep quality is measured using the Pittsburgh Sleep Quality Index (PSQI) at baseline and 6 months 11. Cognitive function is measured using the Stroop test at baseline and 6 months 12. Musculoskeletal symptoms are assessed using the Standardised Nordic Questionnaire at baseline and 6 months 13. Work engagement (characterised by vigour, dedication, and absorption) will be measured using the Utretcht Work Engagement Scale (UWES) at baseline, 6 months, and 8-11 months 14. Occupational fatigue is measured using the Need for Recovery Scale at baseline, 6 months, and 8-11 months 15. Job performance and job satisfaction is measured using single-item 7-point Likert scales atbaseline, 6 months, and 8-11 months 16. General quality of life is assessed using the WHO QOL-BREF at baseline, 6 months, and 8-11 months 17. Presenteeism is assessed using the Work Limitations Questionnaire and the Wor | — |
Countries
England, United Kingdom
Contacts
Public ContactAlison Stanley
Outcome results
None listed